Daiichi Sankyo
211 Mt. Airy Road
Basking Ridge
New Jersey
07920
United States
Tel: (908) 992-6400
Website: http://www.daiichisankyo.com/
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.
With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.
For more information, please visit: www.daiichisankyo.com.
Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.
STOCK EXCHANGE: Tokyo Stock Exchange
STOCK SYMBOL: 4568
487 articles about Daiichi Sankyo
-
Daiichi Sankyo, Inc. Release: New Data Show Olmesartan, An Angiotensin Receptor Blocker (ARB) Has Significant Anti-atherosclerotic And Vascular Protective
9/24/2007
-
Daiichi Sankyo, Inc. and Forest Laboratories, Inc. Sign Letter of Intent for Co-Promotion of AZOR(TM); Forest to Pay Daiichi Sankyo Upfront Payment $20M
8/21/2007
-
Daiichi Sankyo, Inc. Release: Fifth Sankyo Takamine Memorial Award Announced
7/13/2007
-
KineMed, Inc. Evaluates the Mechanism of Action for Colesevelam in Patients With Type 2 Diabetes
5/21/2007
-
Daiichi Sankyo, Inc. Release: BENICAR HCT(R) Reductions in Seated Systolic Blood Pressure for Stage 2 Patients Compared With Amlodipine + Benazepril
5/21/2007
-
Daiichi Sankyo, Inc. Release: Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5/21/2007
-
Daiichi Sankyo, Inc. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5/21/2007
-
American Society of Hypertension and Daiichi Sankyo, Inc. Release: BENICAR HCT(R) Reductions in Seated Systolic Blood Pressure for Stage 2 Patients Compared With Amlodipine + Benazepril
5/21/2007
-
YM BioSciences' Partner Daiichi Sankyo, Inc. Receives Clearance for Initial Clinical Trial in Japan
4/17/2007
-
Sanofi-Aventis (France) Gets Daiichi Panaldine Japan Rights
4/2/2007
-
Daiichi Sankyo, Inc. Announces Filing for WelChol Label Change to Include Ezetimibe Efficacy Data
3/28/2007
-
US FDA Warns Japan's Daiichi Over Drug Promotions
1/22/2007
-
Daiichi Sankyo, Inc. And Eli Lilly and Company Release: Enrollment Completed In Pivotal Phase III Study Comparing Prasugrel To Clopidogrel In Patients With Acute Coronary Syndrome
1/16/2007
-
Daiichi Sankyo, Inc. Announces Filing Of New Drug Application For Amlodipine Besylate / Olmesartan Medoxomil Combination For The Treatment Of Hypertension
11/28/2006
-
Daiichi Sankyo, Inc. Release: New Study Confirms WelChol Improves Glycemic Control In Patients With Uncontrolled Type 2 Diabetes Mellitus On Insulin
11/16/2006
-
Daiichi Sankyo, Inc. Release: First Study To Evaluate WelChol/Ezetimibe And Simvastatin Effect On LDL-C Finds Additional Lipid Parameter Benefits
11/13/2006
-
Daiichi Sankyo, Inc. To Transfer Chemical Products Business Of Sankyo Lifetech
10/30/2006
-
Daiichi Sankyo, Inc. Subsidiary Applies For Additional Indication For Fentanyl Injection
10/2/2006
-
Daiichi Sankyo, Inc. To Invest $60 Million In Kearney Venture Partners, L.P.
9/8/2006
-
Sankyo To Manufacture, Distribute Olmetic Antihypertensive Drug In China
8/4/2006